Citation map · Study

Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System

13 references·0 citing·52 second hop

this work references cited by second hop

References

2018The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment873 cited
2010Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers255 cited
2018Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies168 cited
2017Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund162 cited
2014Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden156 cited
2011What principles should govern the use of managed entry agreements?155 cited
2012Coverage with Evidence Development, Only in Research, Risk Sharing, or Patient Access Scheme? A Framework for Coverage Decisions144 cited
2018Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC—Does the Presence of an Explicit Threshold Affect the ICER Proposed?115 cited
2017Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics84 cited
2014The Impact of Out-of-Pocket Payments on Health Care Inequity: The Case of National Health Insurance in South Korea61 cited
2016Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways54 cited
2014Managed entry agreements for pharmaceuticals in Australia51 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

Cited by

No citing works inside the corpus for this window.